Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | IDH inhibitors for AML: highlights from ASH 2018

Marina Konopleva • 18 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Enasidenib Ivosidenib

Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on the key news for IDH1/2 inhibitors for acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Marina Konopleva

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more 21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Aditi Shastri et al. • 19 Sep 2025
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN 1:48
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
Marina Konopleva • 13 Jun 2025
Ongoing trials investigating novel treatments for younger and older patients with AML 3:02
Ongoing trials investigating novel treatments for younger and older patients with AML
Marina Konopleva • 13 Jun 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals